CAMP4 Therapeutics Corporation Common Stock (CAMP) Stock
Fundamentals
Recent news

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP

CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP

New Strong Sell Stocks for July 16th
New Strong Sell Stocks for July 16th
CAMP

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 6 articles
published over the past 14 days
Latest news

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP

CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP

New Strong Sell Stocks for July 16th
New Strong Sell Stocks for July 16th
CAMP

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP

Top 3 Tech Stocks Which Could Rescue Your Portfolio This Month - Digital Turbine (NASDAQ:APPS), CalAmp (NASDAQ:CAMP)
Top 3 Tech Stocks Which Could Rescue Your Portfolio This Month - Digital Turbine (NASDAQ:APPS), CalAmp (NASDAQ:CAMP)
CAMP

Best Penny Stocks Today? 3 That Funds & Insiders Are Buying Now
Best Penny Stocks Today? 3 That Funds & Insiders Are Buying Now
CAMP
About CAMP4 Therapeutics Corporation Common Stock
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joshua Mandel-Brehm | CEO, President & Director | 1983 |
| Dr. Richard A. Young Ph.D. | Founder & Independent Director | 1954 |
| Ms. Kelly Gold | Chief Financial Officer | 1977 |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer | 1981 |
| Dr. Leonard I. Zon M.D. | Founder & Chairman of Scientific Advisory Board | — |
| Mr. Caleb Moore | Chief Business Operations Officer | — |
| Dr. Daniel Tardiff Ph.D. | Chief Scientific Officer | 1980 |
| Ms. Michelle Gates | Senior VP & Chief People Officer | — |
| Ms. Alla Sigova Ph.D. | Senior Vice President of Platform | — |
| Dr. Satya Kuchimanchi Ph.D. | Senior Vice President of Technical Operations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.1 | -6.0 | -6.3 | -22.4 | ||||||||
| 2022 | -16.5 | +17.9 | +5.9 | -23.6 | +26.3 | -41.8 | +10.8 | +25.9 | -31.3 | -3.3 | -5.5 | +25.1 |
| 2023 | +3.1 | -9.5 | -17.5 | -27.2 | -28.7 | -40.4 | -12.3 | -34.5 | -35.6 | -42.1 | +38.2 | -19.9 |
| 2024 | -46.1 | -18.4 | +20.0 | -4.3 | -19.1 | -35.6 | ||||||
| 2026 | -29.8 | -6.5 | +8.4 | +8.2 | -20.5 | -5.9 | +3.4 |



